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Abstract:
High rates of antibiotic use have resulted in the pervasiveness of multi-drug resistant
organisms. With rising drug-resistance the development of antibiotics with new targets against
these pathogens is imperative. The T-box regulatory mechanism is a process specific to Grampositive bacteria and controls many essential genes including aaRS genes, which are code for the
aminoacyl-tRNA synthetases required to charge tRNA. The T-box Specifier Loop is a novel
target for antibacterial drug discovery as we hypothesize that a small compound bound to the
Specifier Loop will inhibit transcription of essential bacterial genes resulting in bacterial cell
death or growth arrest. We used an in silico drug discovery approach combined with structureactivity relationship studies (SAR) to evaluate small molecules as potential putative antibiotics
directed against Gram-positive bacteria. SAR studies have been used to determine important
structural elements of the initial hit compounds so that a compound with optimal activity and
Gram-positive selectivity can be developed into an antimicrobial agent.
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Introduction:
Many drug-resistant pathogens have risen in frequency and lethality. High rates of
antibiotic use have resulted in the pervasiveness of advantageous mutations against antibiotics.1
This epidemic of resistance has developed from increased frequency of prescription, which is
supported by studies showing a positive correlation between the amounts of regional antibiotic
consumption with the rate of prevalence of antibiotic resistant bacterial infections. The US
Centers for Disease Control and Prevention conservatively approximate 2 million illnesses and
23,000 deaths annually as a consequence of resistance (Zhang et al)2 An increase in resistance of
bacterial infections in healthcare facilities is beginning to reduce the amount of available
antimicrobial agents. Thus, the development of antibiotics with new targets against multi-drug
resistant organisms is imperative. Addressing the issue of resistance has brought a focus onto
nosocomial infections that are developing strong resistance to current antibiotic treatments. 1
Gram-positive bacterial infections have demonstrated increasing resistance despite many
attempts to preclude the evolution of these microorganisms. Gram-positive cocci bacteria
specifically demonstrate dangers as strains such as, Methicillin Resistant Staphylococcus aureus
(MRSA), Penicillin Resistant Streptococcus pneumoniae (PRSP), Vancomycin Resistant
Enterococci (VRE), and many others have broadened resistance to many of their current
treatments. A surveillance study, conducted on nosocomial infections and their transmission
throughout 463 hospitals in China, demonstrated that the prevalence of MRSA was much higher
in ICU patients (77.6%) than in both inpatients (50.2%) and out patients (26.1%). Evaluation of
the prevalence of resistant strains conducted during 2006-2007 demonstrated that across the 463
hospitals all had at least 1 hospital associated infection (HAI). Further data showed that 28,502
HAIs were reported across 25,384 patients, which reflects the frequency of nosocomial

infections. On the basis of this study, the 10 most common HAIs were determined in these
hospitals and the 3 most prevalent of these infections were Gram-positive organisms.3
The excessive use of antibiotics in a variety of circumstances, which may be deemed
inappropriate or unnecessary, have resulted in the acceleration of resistance. Estimates
approximate that about 50% of prescribed antibiotics are inappropriate. The development of new
antibiotics with decreased opportunity for resistance is integral as research must be cost effective
in searching for new antimicrobial treatments.4 There have only been three new classes of
antibiotics that have been introduced since the year 2000. Thus, the need for non-toxic antibiotics
against multi-drug resistant Gram-positive organisms is crucial.5 Comprehension of current
antibiotic mechanisms is an essential aspect of understanding the development of resistance and
how to find future antibacterial agents to combat these evolving organisms. There are 5 major
target mechanisms of which current antimicrobials interfere or inhibit, including (1) cell wall
synthesis; (2) protein synthesis; (3) nucleic acid synthesis; (4) a metabolic pathway; or (5) the
bacterial membrane structure.4
Evolutionary adaptations have allowed bacterial infections to evolve several mechanisms
of resistance. Intrinsic resistance is the use of a natural mechanism that is innate to a bacterium.
Acquired resistance, on the other hand, is the development of spontaneous mutations or
acquisition of genes through methods such as horizontal gene transfer. Four major mechanisms
of resistance have arisen including alteration of antibiotic binding site, creation of enzymes that
inactivate or destroy the antibiotic, development of an efflux pump, and development of a porin
or channel that prevents entry of an antibiotic into the cell.4
There are many modifications that can occur in the binding site of the antibiotic and can
prevent it from acting on its target.4 This mechanism is one of the ways Gram-positive organisms

have evolved against Beta Lactams, which are some of the oldest currently used antibiotics. This
class of antibiotics includes many molecules, all of which contain a B-Lactam ring, including
Penicillins, Cephalosporins, and Monobactams. The mechanism of action for these antibiotics is
to interfere with enzymes such as transpeptidases, carboxypeptidases, and endopeptidases, which
are necessary for the building and maintaining peptidoglycan of the cell wall. These enzymes are
often referred to as Penicillin Binding Proteins (PBPs). Many Gram-positive organisms have
developed resistance that interferes with these antibiotics binding site. S. pneumoniae became
resistant to Penicillins and Cephalosporins as a result of a mutation in the PBP gene, causing the
antibiotic target site to be modified. These modifications rendered these drugs ineffective
because the organism developed PBPs that no longer could bind the Beta Lactam ring. Both S.
aureus and Enterococcus faecium developed resistance to antibiotics in the Beta Lactam class
via target site modification. The development of this type of resistance is dangerous, as they are
genetically transferrable across species allowing other bacterial strains to create mutant PBPs. 6
Another extremely common method of resistance is the evolution of enzymes that have
developed the capability to inactivate drugs. This method of resistance has caused great
devastation to current treatments.4 The Gram-positive bacteria Mycobacterium tuberculosis has
developed resistance to the aminoglycoside (AG), Kanamycin A (KAN), which targets the 30s
ribosomal subunit. M. tuberculosis was able to adapt through the development of mutations on
the promotor region of the eis (enhanced intracellular survival) gene resulting in a gain of
function of AG acetyltransferases, which acetylates the antibiotic destroying its activity. In this
case, M. tuberculosis developed AG acetyltransferases that are capable of acetylating the amino
group of KAN causing inactivation. This gene has been seen in other organisms and can pose a
great danger to the ability to treat this multi-drug resistant Gram-positive pathogen that has

shown incredible resilience.7 Resistance such as this has occurred in Gram-positive organisms
against other antibiotics such as, Beta Lactams, which are hydrolyzed on the beta lactam ring by
Beta Lactamases resulting in inactivity.4
The development of efflux pumps is an example of intrinsic resistance that can
potentially eradicate currently used antibiotics. Some estimates predict that 5-10% of bacterial
genes contribute to this function.8 In many cases, if this mechanism develops against a nonspecific antibiotic, then it will likely prevent the effectivity of the other antibiotics with a similar
mode of action, making this mechanism highly dangerous. Gram-positive pathogens utilize this
resistance mechanism for a variety of antimicrobial agents. Organisms have developed efflux
mechanisms against several antibiotics from the fluoroquinolone class including ciprofloxacin,
norfloxacin, and ofloxacin. These antibiotics target DNA synthesis machinery, including DNA
gyrase and topoisomerase.4 Efflux pumps are more precarious than other methods of resistance,
in that they may be a bridge as a single step mutant can result in a multi-drug resistant pathogen.
This occurs when low level resistance created by efflux pumps to one antibiotic in the class
eventually results in resistance to several antibiotics within the class.8
The final mechanism is the altering of porin channels that prevent drug entry, which
lowers the antibiotic concentration in the cell. This mechanism is more common in Gramnegative organisms because they have an additional outer membrane that consists of a lipid
bilayer.4 Porins are open pores in the membrane and antibiotics are able to pass through these
pores to gain easy access into the cell. This is especially effective as many of the antibiotics that
are currently used have intracellular targets. Bacterial cells can develop resistance to this through
alteration to the voltage and conductance of these porins putting them into a closed or inactivated
state that will not allow entry of the antibiotic into the cell. This mechanism is utilized by many

Gram-negative pathogens

such

as,

Pseudomonas

aeroginos,

Neisseria

gonorrhoeae,

Enterobacter aerogenes, klebsiella pneumonia and many others.9 However, this can occur in
Gram-positive pathogens, such as Vancomycin-intermediate S. aureus (VISA), which displays
phenotypic passage-selection against the antibiotic Vancomycin resulting from the development
a thickened peptidoglycan wall to prevent Vancomycin access into the cell.10
With resistance on the rise and Gram-positive infections utilizing many mechanisms to
combat all current treatments, there is a desperate need for the development of new antibiotics.
In 2013, Gram-positive organisms appeared in all three categories of CDC’s levels of concern
including Urgent Threats, Serious Threats, and Concerning Threats. The economic effects of
these infections have been devastating due to the expense of hospitalization and loss of work
force. Approximations for the year 2008 are 20 billion dollars in healthcare expenses exacerbated
by an additional estimated cost of 35 billion dollars from loss of work productivity.11
Currently, the most dangerous Gram-positive organism is Clostridium difficile, which has
had catastrophic effects on American society causing 250,000 infections and 14,000 deaths per
year. This organism was classified as an Urgent Hazard Level due to its potential to become
widespread across the country. C. difficile occurs on a nosocomial and non-nosocomial basis
costing 1 billion dollars in excess medical costs per year. This microorganism has had a drastic
impact on the senior citizen population; killing 90% of the senior citizens that it infects. Other
dangers include, Drug-Resistant S. pneumoniae, which is currently considered at Serious Threat
Level and causes 1.2 million infections annually, 7000 deaths, and costs 19,000 dollars in excess
hospitalizations. Approximately, 160,000 children under the age of 5 will be admitted into a
hospital as a result of this Gram-positive infection. Several other resistant organisms have also
bombarded the healthcare system. S. aureus has expanded its resistance against many of the past

successful antibiotics. With new strains evolving against current antibiotics, including methicillin
resistant S. aureus (MRSA) and Vancomycin-resistant S. aureus (VRSA), which are Serious
Threat and Concerning Threat levels respectively. It is essential that new antibiotic targets are
discovered against Gram-positive bacteria.11,12
All of these infections are evolving resistance via aforementioned mechanisms and
resulting in drastic health care costs, morbidity and mortality. The resistance rate has drastically
increased as treatments of patients in chemotherapy, complex surgery, afflicted with rheumatoid
arthritis, dialysis for renal disease or receiving organ and bone marrow transplants all pose high
risk for infections. The use of antibiotics in these patients breeds resistance because of decreased
ability to fight infection as a result of immunodeficiency. In many cases certain antibiotics
cannot be used or are dose limited because of the toxicity in patients with some of these
conditions, posing a great threat for the development of resistance. This is due to the fact that
low doses expose many bacteria to the antibiotic, but may not effectively kill every viable cell.
This may result in spontaneous mutations that create resistance to an antibiotic. Ultimately, even
limiting the over-prescription of antibiotics, preventing infection, and tracking infections will
only slow and not eliminate the problem of resistance.11
RNA has increasingly become recognized as an advantageous target for antibiotic drug
development in the fight against antibiotic resistance. The integral nature of RNA in the genetic
and functional processes of a cell makes it a desirable target for drugs. Riboswitches are RNA
regulatory elements that change structural conformation upon metabolite or ligand binding to
alter gene expression. These metabolite sensing regulators are energetically conservative as they
almost exclusively occur at the 5’UTR preventing unnecessary transcription of the operon. The
region with the most conservation is the four nucleotide binding domain that is often referred to

as the “aptamer” domain. Interaction at this aptamer domain results in a second binding event at
the “expression platform”, which determines whether or not downstream gene expression will
occur.13
The T-box regulatory mechanism is not a riboswitch in a conventional sense, but it
functions very similarly in its method of regulation. This regulatory element’s is specific to
Gram positive bacteria and is used by many operons encoding essential genes. One essential
gene that is regulated through this mechanism is the aaRS gene, which is responsible for making
aminoacyl-tRNA synthetases. These enzymes are essential for catalyzing reactions that charge
the tRNA with the proper amino acids. 14 Regulating at the transcription attenuation level, the Tbox mechanism efficiently uses the binding of a charged and uncharged tRNA species to regulate
translation of amino-acid related genes, such as amino-tRNA synthetases and amino acid
transporters. The tRNA species anticodon specificity is essential to regulation as deviation in a
single nucleotide can result in a significant decrease in expression of genes.15
T-box regulation consists of a specific tRNA binding to two distinct regions in the 5’
UTR. Figure 1 illustrates these binding events and the formation of both the attenuation and
downstream reading events. The first interaction occurs in stem I at the Specifier Loop where a
base pair binding event between the anticodon of a specific tRNA and the Specifier Loop on
Stem I of the 5’UTR occurs. After the first binding event, a second binding event will occur at
the second Loop taking the form of one of two potential structures, a terminator or antiterminator
helix. If the binding tRNA is charged, the amino acid present prevents stabilization of the
antiterminator helix and a terminator Loop is formed, resulting in no downstream reading of the
operon. The T-box mechanism is predisposed to termination as the terminator helix is a more
thermodynamically stable structure then the anti-terminator helix. However, if an uncharged

tRNA is bound to the Stem I Specifier Loop, then the interaction will promote a second binding
event between the NCCA sequence at the acceptor end of the tRNA and the UGGN residues of
anti-terminator bulge region in Stem II of the mRNA 5’UTR. This interaction prevents the
formation of the terminator helix allowing for expression of the downstream coding sequences.15
Specific tRNA recognition by the nascent transcript will result in an increased expression of the
genes imperative to tRNA aminoacylation.14
Figure 1

Figure 1:
“The T box mechanism. Expression of genes in the T box family is regulated by the ratio
of charged to uncharged tRNA in the cell. (A) Aminoacylated tRNA binds only to the
Specifier Loop; the presence of the amino acid prevents interaction of the acceptor end of
the tRNA with the antiterminator. The more stable terminator helix (blue-black) forms
and transcription terminates. (B) Uncharged tRNA interacts at both the Specifier Loop
and the antiterminator; this stabilizes the antiterminator (red-blue) which sequesters
sequences (blue) that otherwise participate in formation of the terminator helix, and
transcription reads through the termination site and into the downstream coding sequence.
Binding of uncharged tRNA results in structural changes throughout the leader RNA. The
tRNA is shown in cyan; the amino acid (aa) is shown as a yellow circle attached to the 3′
end of the charged tRNA. Positions of base-pairing between the leader RNA and the
tRNA (Specifier Loop–tRNA anticodon, antiterminator bulge–tRNA acceptor end) are
shown as green lines.”
Description and Image Adapted from:
Nicholas J. Green , Frank J. Grundy , Tina M. Henkin
“The T box mechanism: tRNA as a regulatory molecule”
FEBS Letters, Volume 584, Issue 2, 2010, 318 – 324
http://dx.doi.org/10.1016/j.febslet.2009.11.056

As aforementioned, this process requires Specifier sequence recognition of the tRNA
anticodon and the anti-terminator bulge that interacts with the acceptor end of the tRNA. The
tRNA recognition site has an apex region with an adenosine-guanine bulge that is referred to as
the distal Loop. The Loop to Loop structural region serves as a docking platform for the tRNA to
bind for gene expression. This marks some of the major similarities to the structural events that
occur in a conventional riboswitch.14 Further evidence to support the riboswitch nature of this
mechanism is that in vivo and in vitro studies demonstrate that a single tRNA in its entirety is
sufficient to promote the regulatory response.16
The genes encoded by the T-box mechanism are essential genes for bacterial growth and
proliferation. Multiple T-boxes are present in a single organism. Many Gram-positive bacteria
such as, Bacillus Subtilis and S. pneumoniae, which have been shown to contain T-boxes
upstream of valS, pheS, pheT, glyQ, glyS, thrS, and ileS genes as well as for other genes as
well.17 The T-box Specifier Loop is a novel target for antibacterial drug discovery as we
hypothesize that a small compound bound to the Specifier Loop will inhibit transcription of
essential bacterial genes resulting in bacterial cell death or growth arrest. Due to the conserved
nature of the Specifier Loop there is potential for a broad spectrum of antibacterial activity
against Gram-positive pathogens. Since there are multiple T-boxes within each bacterium, there
is a decreased chance of resistance emerging, as a single small molecule antibiotic could shut off
multiple T-boxes limiting the bacteria’s ability to evolve by altering the antibiotics binding site.
The high conservation of this region suggests that any major alteration to this binding site may
result in a loss of function and bacterial cell death. The T-box regulatory mechanism is not
present in eukaryotic cells, which reduces the potential for cytotoxicity. With these factors in

mind, a small molecule that can bind to T-boxes and disrupt gene regulation is a strong candidate
for development of new antibiotics.16
Using in silico analysis of the T-box Specifier Loop, small compounds that are likely to
disrupt T-box function were identified. Bacterial growth arrest studies identified three initial hit
compounds, one of which demonstrated Gram-positive specificity and displayed moderate-tolow cytotoxicity in human cells. Based on this data, structure activity relationship studies (SAR)
were conducted with disk diffusion assays against S. aureus with structural analogs of our initial
hits. Minimum Inhibitory Concentration (MIC) assays and Minimum Bactericidal Concentration
(MBC) assays were conducted against S. aureus and the Gram-negative bacterium Escherichia
coli for analogs that displayed antibacterial activity with disc diffusion assays. Using the
successful compound structures as a template, an additional in silico docking study was
conducted on selected analogs with structures identified as essential to antibiotic activity. Top
candidates of this docking simulation as well as other carefully selected analogs will be tested
using both MIC and MBC assays to further assess and refine structural determinants required for
antibacterial activity. These SAR studies have allowed for the determination of important
biochemical features for Gram-positive activity including, the heterocyclic thiazole, norbornane
carboxylic acid, and benzene. Evidence suggests that a meta orientation on the benzene ring
between the thiazole and a long carbon chain may produce optimal antimicrobial activity.

Methods:
Chemical Compound Re-suspension:
Compounds were commercially available and purchased from Ambinter, Asinex,
Enamine, Akos, Molport, Prinston Biomoleular and Chembridge. All compounds that were used
for the experiments were suspended in 100% DMSO at a concentration of 15 mg/mL for disk

diffusion assays and 10mg/mL for MIC assays. DMSO was chosen because many of the
compounds displayed poor solubility in the presence of standard media or water. All compounds
were aliquoted and stored at -80°C until the day of the experiment. Individual aliquots of
compound, gentamicin and DMSO were thawed on ice on the day of an experiment. Control
antibiotics were prepared in 100% H2O, and stored at -20°C until experimental use.
Bacterial Culturing:
Staphylococcus aureus, subsp. aureus Rosenbach ATCC 29213 (ATCC) was used for all
anti-microbial activity experiments. This strain was used as it is laboratory strain of S. aureus
commonly used for anti-microbial activity testing. For each experiment, different types of
media’s were used, Tryptic Soy Broth (TSB) and Luria Bertani agar (LBA). The TSB (Sigma)
was used for growth of liquid cultures and prepared water as per manufacturer’s instructions, and
supplemented with 2.5 g of dextrose per liter of media as a preferred carbon source. Media was
sterilized by autoclave. An overnight culture was set up prior to each experiment by placing a 34 morphologically similar colonies of S. aureus into a sterile culture tube with 3 mL of TSB. The
culture was placed in a shaking incubator at 37 °C for 18 hours at 225 rpm. After 18 hours a new
culture was prepared so that the bacteria would be in the logarithmic stage of growth for each
experiment. Using the overnight culture, 60 µL of bacterial culture was pipetted into a new tube
of 2.94 mL of TSB. This culture provided a 1:50 ratio of bacteria to media and was placed in the
shaking incubator at 37°C for 3-4 hours prior to the experiment so that bacterial culture would be
in logarithmic stage of growth. An OD600 reading between 0.4-0.8 indicates exponential growth
stage. LB agar was chosen as solid media for antibiotic susceptibility testing. The media was
made with a ratio 35 g of media per liter of DI water as per manufactures instructions. Media
was sterilized by autoclave and poured into sterile petri dishes with a volume of 25 mL in each

plastic petri dish to ensure reproducibility. All media was made and poured under sterile
conditions to prevent contamination. Plates were stored at 4°C.
Disk Diffusion Assay:
The antimicrobial susceptibility testing was done using the Kirby-Bauer disc diffusion
method. Disk diffusion assay protocol was modeled after Bauer et al.18 Under sterile conditions
disks were placed on a prepared sterile sheet of aluminum foil and compounds were spotted onto
each disk at a concentration of 150 µg/mL. A sterile cotton swab was dipped into the bacterial
solution of S. aureus and then used to completely cover the surface of a pre-warmed LB agar
plates. Plates were dried in an incubator for 10 minutes and then the spotted disks were placed
onto the inoculated petri dishes antibiotic side down to maximize compound diffusion through
the agar. Following incubation for 18 hours at 37 °C, the zones of inhibition were measured and
photographed. After all compounds were tested in triplicate, those with ambiguous results were
retested in triplicate at a higher concentration of 300 µg/mL using the same procedure stated
above. This was done so that all compounds that successfully inhibited bacterially growth could
be determined accurately.

Minimum Inhibitory Concentration (MIC)/Minimum Bactericidal Assays (MBC):
The minimum inhibitory concentration assay is used to determine the lowest
concentration that an antimicrobial can inhibit visible growth of bacteria. The results of the MIC
assay can be used to conduct a minimum bactericidal assay, which is used to determine the
lowest effective concentration that an antimicrobial kills all viable bacteria. Prior to the
experiment all The MIC assay was set up using a 96 well plate. All MICs and MBC
antimicrobial testing was conducted based on the NCCLS standard with modifications.19

Compounds were serially diluted 2-fold from 481 µg/mL to 0.23 µg/mL. There was a sterility
control well containing 100 μL TSB where no inoculum was added. A growth control well was
implemented with 80μL TSB to which 20 μL standardized inoculum was added. A DMSO
control was used to ascertain the growth level in the presence of solvent without compound,
which was used to demonstrate any impact of the presence of the final 4.81% DMSO.
Additionally, Gentamicin, a clinical antibiotic, was used as a control and was serially diluted two
fold from 48.1 µg/mL to 0.092 µg/mL to confirm expected MIC against laboratory strain of use.
A culture in exponential growth was diluted as per the McFarland Standard to OD600 of 0.08 to
0.12 which contains 1-2x108 CFU/mL. After an additional 1:2.5 dilution was carried out. All
wells were inoculated within 15 minutes of dilution with 20 µL containing 8x105 CFU/mL.
After all necessary wells were inoculated and thoroughly mixed, a micro plate reader was used to
measure the OD600 of each well. The plate was then allowed to shake at 100 rpm at 37°C in the
incubator for 20 hours. After this time period, another OD600 reading was taken to determine a
change in optic density. This provided a quantitative determination to whether or not there is
bacterial growth. The MIC was determined as the lowest compound concentration at which no
visible growth was observed. Criteria for MIC was assessed using graphed data assigning a MIC
value based on the concentration that showed close to a 100% inhibition just prior to a large
increase in growth.
To determine the MBC, all wells from the MIC experiment with a concentration equal or
greater than the MIC were individually spread onto separate dishes of LB agar and incubated at
37°C for 24 hours. The MBC was recorded as the lowest compound concentration where there
were no viable bacterial colonies. If the MBC was is no more then 4 fold of the MIC of a specific

compound then this compound was determined to be bactericidal and if it was not then it was
deemed bacteriostatic.
In silico screening:
Using in silico analysis, 250,000 small molecules were screened to determine
compounds likely to bind to the T-box Specifier Loop of the Gram-positive bacterium, Bacillus
subtilis. Of this large small molecule database, 200 molecules showed potential to disrupt T-box
function. This work was conducted by Albany Molecular Research Institute using sophisticated
computer technology that assessed the binding energy of small molecules to the target. From this
list of 200 compounds, 28 of these were selected for bacterial growth arrest studies. Figure 2
demonstrates the progression of compounds from the initial in silico to the analogs currently
being tested. Biological testing resulted in the identification of two initial hit compounds PKZ
1800, and PKZ 0600, which became the focus for structure-activity relationship studies based on
their greater antimicrobial activity and Gram-positive selectivity. To narrow necessary structural
elements for antimicrobial activity, we began SAR studies of analogs of these two initial hit
compounds. SAR round 1 was conducted with disk diffusion assays against S. aureus using 20
structural analogs of parent compound PKZ 1800 and 15 analogs of PKZ 0600. An additional 15
compounds were tested from the original list of 200 in search of more effective small molecule
families then current initial hits under SAR evaluation.
Based on the data provided by both the disk diffusion and liquid screening assays,
structural searches were conducted in small molecule libraries that are publicly available. These
searches were based on modifications to parent compound PKZ 1800 in a chemical draw
program so that analogs with specific desired structures could be found. An additional in silico
analysis was done by The RNA Institute of 22 compounds chosen from these chemical libraries.

This additional in silico was conducted to determine binding energies of these new potential
compounds for future testing in search of a PKZ 1800 analog that may have improved biological
activity. Binding energies of each compound for the second in silico were ascertained and
compared to prior successful parent compound PKZ 1800 as well as ethanol as a negative
control.
Figure 2:

Figure 2
This figure demonstrates the chronological of compound testing and
selection. It reflects the initial testing done that identified the first 2 hit
compounds all the way until the current PKZ 1800 analogs being tested in
the second round of SAR studies.

Liquid-Culture Screen:
Structural analogs PKZ 1821-1834 were tested in an initial screening at a concentration
of 500µg/mL or 250 µg/mL, depending on solubility restraints. This initial testing was to
determine which compounds demonstrate antimicrobial activity so that a full MIC assay could be
conducted against both S. aureus and E. coli for the successful compound. To a 96-well plate we
added 170 µL of media, 20 µL of media with inoculum, and 10 µL of 10 mg/mL compound for
500 µg/mL final concentration or 5 µl of 10 mg/ml compound for 250 µg/mL final. Controls
included a sterility control (TSB only), a positive growth control (TSB+bacteria), and DMSO
control (5%DMSO+TSB+bacteria). Additionally, a titration of Gentamicin from 50 µg/mL to 0.1
µg/mL was used to confirm there was no contamination by ensuring that the anticipated MIC of
Gentamicin against the lab strain used was seen. Compound inhibition was determined
quantitatively by measuring OD600 reading immediately after well inoculation and re-measuring
following a 20 hour incubation period with plate shaking at 100 rpm at 37°C. Inhibition was
determined by the change in OD600 after the incubation period. If there is increase in optical
density over the incubation period it demonstrates that bacterial growth is present.

*The following information is proprietary and should be considered confidential. Please
contact Dr. Paul Agris for permission prior to publishing.

Results:
Antibacterial testing of 15 Distinct Chemical Families:
The first in silico yielded 200 compounds likely to disrupt T-box function and 28 of these
compounds had been screened for activity. With 2 initial hits being pursued for SAR studies the
search for potential more effective chemically distinct families continues. There 15 molecules of
chemically distinct families screened during SAR studies. First disk diffusion assays were
conducted at 150µg/mL against S. aureus to see if there was antibacterial activity. Of these 2
compounds there were 2 that showed potential inhibition, but the results were ambiguous. To
further ascertain there potential these compounds were screened at 300µg/mL, where they
showed effectivity. These compounds were then tested in micro-dilution assays to determine
the MIC and MBC concentrations. The results of these compounds screens are reflected by
Table I. Both of these compounds, PKZ 0024 and PKZ 0034 showed no Gram-positive activity.
PKZ 0034 demonstrated no activity against E.coli or S.aureus and PKZ 0024 showed activity
against only E.coli at 481 µg/mL.

Table I: Distinct Chemical Families from AMRI Docking
AMRI docking
Top 200 molecules
0021
0022
0023
0024
0025
0026
0027
0028
0029
0030
0031
0032
0033
0034
0035

Zone of Inhibition (cm)
Concentration 150µg/mL

Zone of Inhibition (cm)
Concentration 300µg/mL

NI

NT

NI

NT

NI

NT

1.05 *
NI

1.31*

NI

NT

NI

NT

NI

NT

NI

NT

NI

NT

NI

NT

NI

NT

NI

NT

NI
NI

0.956*
NT

NT

Compound

S. aureus MIC (MBC)

E. coli MIC (MBC)

0024

N/O (N/O)

481 (N/O)

0034

N/O (N/O)

N/O (N/O)

Table I: Legend
NI= No Inhibition
NT= Not Tested
MIC = Minimum Inhibitory Concentration Assay
MBC =Minimum Bactericidal Concentration Assay
N/O= Not observed
IND= Indeterminable
*All concentrations above are in μg/mL

SAR of Initial Hit Compounds PKZ 1800/PKZ 0600:
Previous work has shown that initial hit compound PKZ 0600 demonstrated activity
against various Gram-positive organisms and some Gram-negative organisms. All PKZ 0600
analogs were screened using disk diffusion assays against S. aureus to determine if they had any
activity. Those compounds with antimicrobial activity were selected for MIC and MBC assays.
Table II shows the number of analogs tested and the number that showed activity in disk
diffusion assays. PKZ 0600 had several components to its chemical structure, including a honey
comb of three fused cyclic rings with an amide linkage followed by a carbon chain, leading to a
piperzine moidy. This honey comb includes a fused benzene ring, pyrolidine ring, and partially
unsaturated pyridine ring, which was substituted with an amide, alcohol, and carbonyl group.
PKZ 0600 analogs varied in number and structure of fused rings with alternative structures cyclic
and non-cylic in nature replacing the piperzine moidy.
Compounds PKZ 0601, 0602, 0603, 0606, 0609, 0612, 0613 and 0615 all maintained an
identical honey comb structure to PKZ 0600 including all three substituents attached to the
pyrolidine ring. Variation between these analogs occurs in the alternate structures replacing the
piperizine moidy. Analogs PKZ 0603, 0609, 0613 and 0615 showed antibacterial activity, but
demonstrated no Gram-positive selectivity. Compounds PKZ 0603, 0609, and 0615 showed
antibacterial activity against S. aureus in disk diffusion assays. Table III shows the results of
MIC assays of these compounds against both S. aureus and E. coli. All three of these compounds
demonstrated higher activity against the Gram-negative bacterium E. coli with MIC values of
235µg/mL. These 3 compounds PKZ 0603 0609 and 0615 all had MIC values >235µg/mL
against S. aureus demonstrating less activity against Gram-positive pathogens.

Compounds PKZ 0604, 0605, and 0614 retained the honey comb structure of the parent
compound, but contained an oxygen substituent instead of an alcohol on the partially unsaturated
pyrolidine. Additionally, these compounds varied in there replacement of the piperizine moidy.
Of these compounds only PKZ 0605 was effective and demonstrated minimal activity in disk
diffusion assays, but it was not commercially available so no further testing was conducted. PKZ
0600 analogs showed no specificity to Gram-positive bacteria in micro-dilution assays
suggesting non-specific binding. As seen on Table I there was one exception to this, which was
PKZ 0611. PKZ 0611 demonstrated high Gram-positive antimicrobial activity and no activity
against the Gram-negative bacteria. This compound was unique containing 4 fused cyclic rings
including, 2 piperidine rings with an oxygen substituent fused to pyran ring containing multiple
oxygen substituents and an unsubstituted benzene ring. No obvious structural similarities were
present between this PKZ 0600 analog and the effective PKZ 1800 analogs that showed Grampositive selectivity. There were 8 successful compounds amongst the PKZ 0600 analogs. Of
these compounds, 5 contained a honey comb structure with two fused benzene rings and
piperizine ring, but 6 unsuccessful compounds also had these chemical elements. There was no
single element or combination of elements that were exclusively present in successful molecules
making definitive conclusions difficult to draw.
Prior testing conducted on initial hit PKZ 1800 showed Gram-positive selectivity. It was
proven effective in both solid and liquid media culture screenings and was subject to testing with
a variety of bacterial strains. Disk diffusion assays were conducted to ascertain analogs that had
activity against S. aureus. This was done so that only those compounds with sufficient activity
were tested in MIC and MBC assays. PKZ 1800 analogs revealed many significant findings and
showed three chemical structures that were prominent in all of the compounds with the highest

antibiotic activity. Disk diffusion assays were used to narrow in on compounds with activity
levels of interest so that full MICs were only done on those compounds. Full MIC values were
determined for compounds that showed activity in disk diffusion assays.
There are 3 major components of the parent compound including a Norbornane
carboxylic acid with an amide linkage in a meta orientation to the benzene ring substituent on the
heterocyclic thiazole. Additionally, there was a methyl group ortho to the benzene ring. Of the
20 analogs of PKZ 1800 tested, 13 of these analogs contained the heterocyclic thiazole. All
effective compounds retained this integral feature including compounds 1805, 1808, 1810, 1813,
1819 and 1820. Compounds PKZ 1819 and PKZ 1820 contained the norbornane carboxylic acid,
the heterocyclic thiazole, and the benzene ring identical to the parent compound. PKZ 1820 and
PKZ 1819 showed inhibitory activity at concentrations of 117µg/mL and 481µg/mL respectfully,
but had no activity against E. coli. These compounds differed from the parent compound in their
substituents of the benzene ring. The parent compound has an isopropyl and the thiazole in a
meta orientation on the benzene ring. PKZ 1819 has identical structure to the parent compound,
but has two fluorine’s one ortho and one meta in orientation to the thiazole substituent on the
benzene ring. PKZ 1820 has two chlorines one in ortho position and one in para position. Table
III shows these results demonstrating compounds PKZ 1819 and 1820 have antibacterial activity
and Gram-positive selectivity. PKZ 1813 contained both the norbornane carboxylic acid and the
heterocyclic thiazole, but in replacement of the benzene ring the molecule had a thietane ring
with no substituents. PKZ 1813 was effective in disk diffusion assays, but showed no activity in
MIC assays against S. aureus or E. coli.
Analogs PKZ 1805, 1808, and 1810 contained both the heterocyclic thiazole and the
benzene ring with a cyclohexanoic acid with partial unsaturation in place of a norbornane

carboxylic acid. The benzene ring substituents vary with these compounds with longer and
shorter carbon chains instead of the isopropyl group present on the parent compound. PKZ 1805
showed minimal success in disk diffusion assays and was not available commercially so no
future testing was conducted with this molecule. As seen on Table III, compound PKZ 1808
showed antibacterial activity at the 235µg/mL against S. aureus and 481 µg/mL against E. coli.
PKZ 1808 had some Gram-positive selectivity. PKZ 1810 demonstrated antibacterial activity
with no Gram-positive selectivity having MIC’s of 481µg/mL against both S. aureus and E. coli.
Table II:
Parent Compound

Compounds Tested

Compounds Successful

PKZ 1800

20

6

PKZ 0600

15

8

Table II: Description
This table demonstrates the amount of the structural analogs that
showed activity against that showed activity at <300 µg/mL. Disk
Diffusion assays were used to screen out compounds with activity of
potential interest.

Table III:
Compound

S. aureus MIC

E. coli MIC (MBC)

(MBC)
1808

235 (N/O)

481 (N/O)

1810

481 (N/O)

481 (N/O)

1813

N/O (N/O)

N/O (N/O)

1819

481 (N/O)

N/O(N/O)

1820

117 (N/O)

N/O(N/O)

0603

481 (N/O)

235 (N/O)

0607

481 (N/O)

235 (N/O)

0609

N/O (N/O)

235 (N/O)

0610

235 (481)

235 (481)

0611

58.8 (N/O)

N/O (N/O)

0613

N/O (N/O)

N/O (N/O)

0614

N/O (N/O)

N/O (N/O)

0615

481 (N/O)

235 (481)

Table III: Legend
MIC = Minimum Inhibitory Concentration Assay
MBC =Minimum Bactericidal Concentration Assay
N/O= Not observed
ND= Indeterminable
*All concentrations above are in μg/mL

SAR round 2 of PKZ 1800:
For the next round of SAR PKZ 1800 analogs became the main compound of focus. This
was due to the fact that amongst the PKZ 0600 analogs there was no Gram-positive selectivity
and structural determinations were ambiguous. Additionally, cytotoxicity data conducted by the
Wadsworth center demonstrated that the PKZ 0600 parent compound had far higher cytotoxicity
to mammalian cells then PKZ 1800. With all of these factors considered, efforts were invested in
compounds similar in structure to parent compound PKZ 1800. PKZ 1800 analogs displaying
antibacterial activity and Gram-positive selectivity in SAR round 1 were used as a structural
template for future compounds of testing. Compounds were chosen based on the presence of
specific combinations of structures that might further enhance antimicrobial activity or provide
valuable information about the importance of certain structures. This included compounds both
containing and lacking the benzene ring, methyl group, isopropyl group or norbornane
carboxylic acid. All molecules contained the heterocyclic thiazole. Unique molecules with new
structural elements replacing the norbornane carxboxylic acid were tested in search of a possibly
better replacement for the norbornane structure.
The 22 potential molecules selected were put into an in silico analysis to ascertain
whether these new compounds were likely to bind the Specifier Loop. Top candidates of this
docking simulation as well as other carefully selected analogs were tested at 500 µg/mL to
determine if they were compounds of interest. Using solubility for guidelines, all compounds that
were not soluble enough to determine an accurate determination of growth were used at lower
testable concentrations. This included concentrations that would have an initial OD600 less than
0.7. Table IV shows the results from this initial screen, which yielded 5 compounds with 100%
inhibition at 500 µg/mL. The results of these experiments can be seen on Table IV.

As seen on Table IV, Analogs PKZ 1821, 1822, 1823, 1825 and 1833 showed 100%
inhibition at 500 µg/mL. PKZ 1821, 1822, 1823, 1825, and 1833 have been tested with full MIC
and MBC assays against S. aureus and E. coli (Table V). Analog PKZ 1821 was identical to the
parent compound with the exception of the removal of a single methyl group bound to the
heterocyclic thiazole ortho in relation to the benzene ring. PKZ 1821 demonstrated a MIC of
58µg/mL against S. aureus and no MIC against E. coli. PKZ 1822’s structure includes the
removal of the methyl group and the addition of a carbon to the isopropyl group bound to the
benzene ring making it an isobutyl group. As reflected in Table V, PKZ 1822 had the highest
antibacterial activity and Gram-positive selectivity of any compound tested with a MIC of 29
µg/mL against S. aureus and no MIC against E. coli.
Chemical compound PKZ 1823 lacked the methyl group on the heterocyclic thiazole, and
contained 2 methyl groups on the benzene ring instead of the isopropyl group. This compound
only showed activity at 250 µg/mL in initial screen (Table IV), but did not show any activity in
the full MIC assay testing at < 235 µg/mL (Table V). PKZ 1825 maintains the exact same
structure as the parent compound, but removes the entire isopropyl group from the benzene ring.
Additionally, PKZ 1825 lacks the carboxylic acid. As seen on Table III, PKZ 1825 showed
activity at 235µg/mL against both S. aureus and E. coli suggesting that the carboxlic acid on the
Norbornane is essential for Gram-positive selectivity. The higher activity of PKZ 1821 and PKZ

1822 may suggest the importance of the carboxylic acid present on the norbornane. It also
supports that the methyl substituent on the thiazole rings is not necessary for optimal activity.
Lastly, PKZ 1833 was a unique compound containing an alternative structure to the norbornane.
In addition, this compound lacks the methyl group on the heterocyclic thiazole and has an amide
in replacement of the benzene ring. This is the only compound that demonstrated activity without

the benzene ring. This compound was tested at 500 µg/mL and showed activity (Table IV), but
showed no activity at < 235 µg/mL in the full MIC assay (Table V).
Table IV:
Concentration
(µg/mL)
500

250

Compound

%Inhibition

Solubility

1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1821
1822
1823
1825
1826

100*
100*
100*
47
100*
53*
46
57
44
36
0
31
100
0
100
100
100
100
47

NCS
NCS
NCS
S
NCS
NCS
S
S
S
NCS
S
NCS
NCS
NCS
NCS
NCS
NCS
NCS
NCS

Table IV: Legend
NCS = Not completely soluble
S = Soluble
* = Background OD above 0.7

Table V:
Compound

S. aureus MIC (MBC)

E. coli MIC (MBC)

PKZ 1821

58.8 (N/O)

N/O (N/O)

PKZ 1822

29.4 (IND)

N/O (N/O)

PKZ 1823

250 (N/O)

N/O (N/O)

PKZ 1825

235 (N/O)

235 (N/O)

PKZ 1833

N/O (N/O)

N/O (N/O)

Table V: Legend
MIC = Minimum Inhibitory Concentration Assay
MBC =Minimum Bactericidal Concentration Assay
N/O= Not observed MIC at concentrations <235 µg/mL
IND= Indeterminable
*All concentrations above are in μg/mL

Discussion:
Thorough evaluation of the chemical structures of the first round SAR compounds
suggests that the heterocyclic thiazole is an essential component for antibacterial activity
amongst PKZ 1800 analogs. All successful PKZ 1800 analogs contained this integral structural
feature. Due to the fact that some compounds that were not effective contained the heterocyclic
thiazole, this suggests that the structure is necessary, but may not be sufficient for optimal
activity. The presence of a benzene ring seems to act synergistically with the thiazole ring as all

compounds that depicted significant antimicrobial activity in micro-dilution assays contained the
two connected aromatic structures. Interestingly, neither of these components would ensure the
desired Gram-positive specificity from these antimicrobial agents. Further evaluation of PKZ
1800 analogs revealed that all compounds containing the norbornane carboxylic acid structure
showed specificity towards inhibition of the Gram-positive organisms. PKZ 1800 analogs, PKZ
1808 and PKZ 1810 lacked the selectivity that was seen in PKZ 1819 and 1820. The major
distinguishing chemical element between these pairs of analogs was the presence of a
norbornane carboxylic acid. PKZ 0600 analogs demonstrated no commonalities amongst
successful compounds making structural assertions very difficult. Based on the Gram-positive
selectivity, increased antimicrobial activity, and cytotoxicity, PKZ 1800 analogs became the
main focus of second round SAR studies.
Our structure-activity relationship studies reflected the integral nature of the heterocyclic
thiazole present in PKZ 1800. It was present in all effective PKZ 1800 analogs. Thiazoles have
pharmaceutical significance and have been shown to have a variety of biological functions. They
have led to a variety of antifungals, antioxidants, antibacterial, antitubercular, antidiuretic, antiinflammatory and anticancer activities.20
Currently used thiazole antibiotics have been shown to act on bacterial RNA targets. A
study conducted by Lentzen et al21 showed that thiazole antibiotics thiostrepton, micrococcin,
siomycin, and nosiheptide have a 100 fold higher selectivity for inhibition of bacterial translation
over eukaryotic. Results from this study suggest that thiazole antibiotics nosiheptide,
thiostrepton, and siomycin had a high affinity for the L11 binding domain (L11BD) of 23S
ribosomal RNA and interact to alter its confirmation. 3D modeling revealed stacking interactions
between all four antibiotic thiazole moieties and the quinaldic acid (QA) residue of the rRNA.21

The benzene ring appears to be a significant component as all compounds with
antibacterial activity in second round SAR had this structure. Several compounds tested in the
liquid culture screen assay were almost identical to parent compound PKZ 1800, except without
a present benzene ring and yet these compounds showed no activity. Pi stacking is a potential
mechanism of interaction between a benzene ring and RNA target. Variation in effective
structures may be a result of the diversity of substituents of this element. A recent computation
study by Marcey L Waters22 discusses the strong interactions that can occur between biological
elements and aromatic rings as a result of their hydrophobic nature. This includes interactions
with water where a quadrupole moment may form resulting in an increase in electron density
towards the face the aromatic ring making it more reactive with negatively charged RNA.22 A
study by Cammers-Goodwin et al23 suggested that water can act with the hydrogens of aromatic
rings to facilitate pi stacking.23 Under normal conditions the large presence of water in a cell may
facilitate this type of interaction between a small putative antibiotic and Specifier Loop of the Tbox element. Both aromatic rings including the heterocyclic thiazole and the benzene ring appear
essential for significant activity. Their importance may be because of a hydrophobic stacking
mechanism that promotes interaction between these aromatic rings and the Specifier Loop of a
nascent mRNA.
Antibacterial activity of aromatic rings can be altered drastically by the position and
identity of functional groups substituents. In an antimycobacterial study conducted by Makam et
alREF against M. tuberculosis thiazole compounds linked to benzene rings through amines were
tested and the effectivity of varying substituents and positions were evaluated. In one case, the
presence of an alcohol attached at 2nd, 3rd and 4th positions of the benzene ring resulted in

significant differences in bacterial activity. At the 3rd and 4th position a MIC >200 µM was
seen, but at the 2nd position activity significantly increased, resulting in a MIC of 25 µM.24
Our results are reflective of this as there as changes in activity were observed depending
on the substituents present on the aromatic rings. PKZ 1822 was the most effective compound in
SAR studies. It differed from PKZ 1800 by removal of a methyl group on the heterocyclic
thiazole and presence of an isobutyl group instead of an isopropyl group on the benzene ring.
These alterations may be significant as lengthening the carbon chain on the benzene ring
increases surface area and van der waals forces, which may allow for more efficient binding to
the Specifier Loop. PKZ 1821 had increased activity from past analogs and also lacked the
methyl group on the heterocyclic thiazole. PKZ 1825 demonstrated the least activity and Grampositive selectivity of the three compounds, and still contained the methyl group on the thiazole.
This evidence supports that the methyl group has no contribution to bacterial inhibition and
possibly hinders it. Once main structural elements are revised, a future direction for
consideration would be to conduct thorough evaluation of the effectiveness of various
substituents at different positions on the aromatic rings to further optimize activity.
Determining structural components important for antibacterial activity allows for a faster
and more efficient approach to drug discovery, which has been aided by modern technology.
Resistance is on the rise and the process to discover new and novel antibiotics is extensive and
costly. Utilizing sophisticated computer software is an essential tool in expediting the process to
creating new antibiotics.25 Ultimately, as stated in the CDC threat report the resistance process
can only be “slowed” not stopped.11 Computer-aided drug design (CADD) provides bio-chemical
prediction models such as, in silico, which conducts large scale predictions on chemical
molecules binding energies, poor activity, poor absorption, distribution, metabolism, excretion,

and toxicity preventing wasted time and resources. Newer developments in these technologies
have allowed for efficient discovery with expedited refining of physicochemical and
ADMET/PK (pharmacokinetic) properties.25
With new and efficient models to test molecules there is great need for novel targets.
RNA has a diverse and integral function to transcription regulation, gene expression, and
translation of protein. The diversity and specificity of RNA coupled with its lack of the extensive
repair mechanisms of DNA make it an ideal target for drug discovery. Prior RNA drug targeting
has been directed towards rRNA with drug classes such as aminoglycosides. mRNA and
riboswitch regulator elements on nascent transcripts are novel drug targets for a variety of
reasons. These regulatory elements monitor essential processes for bacterial survival and remain
very distinct from eukaryotic mRNA.26
The combination of rising resistance, decrease in antibiotic innovation, strict US Food
and Drug Administration (FDA) regulation, and lack of economic incentive for pharma
companies, demonstrates the need for efficient methods to drug discovery. RNA targets such as
riboswitches are ideal drug targets because their integral nature in bacterial survival decreases
possibility of resistance and their elucidated structure allows for efficient computerized
approach.27 Using in silico screening and bacterial susceptibility to narrow integral structural
elements allows for the expedited discovery of new novel antibiotic classes, which are
desperately in demand.
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